Filter Results:
(1,253)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
- 2023
- Working Paper
Evaluation and Learning in R&D Investment
By: Alexander P. Frankel, Joshua L. Krieger, Danielle Li and Dimitris Papanikolaou
We examine the role of spillover learning in shaping the value of exploratory versus incremental
R&D. Using data from drug development, we show that novel drug candidates generate more
knowledge spillovers than incremental ones. Despite being less likely to reach... View Details
Frankel, Alexander P., Joshua L. Krieger, Danielle Li, and Dimitris Papanikolaou. "Evaluation and Learning in R&D Investment." Harvard Business School Working Paper, No. 23-074, May 2023. (NBER Working Paper Series, No. 31290, May 2023.)
- September 2022
- Article
Find and Replace: R&D Investment Following the Erosion of Existing Products
By: Joshua L. Krieger, Xuelin Li and Richard T. Thakor
How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using FDA Public Health Advisories as idiosyncratic negative shocks to approved drugs, we first... View Details
Keywords: R&D Investments; Drug Development; Product Shocks; M&A; Biopharmaceutical Industry; FDA; System Shocks; Research and Development; Investment; Decision Making; Pharmaceutical Industry
Krieger, Joshua L., Xuelin Li, and Richard T. Thakor. "Find and Replace: R&D Investment Following the Erosion of Existing Products." Management Science 68, no. 9 (September 2022): 6552–6571.
- December 2019
- Supplement
The Business of Pain: Johnson & Johnson and the Promise of Opioids (B)
By: Erik Snowberg, Trevor Fetter and Amy W. Schulman
This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders.
In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or... View Details
Keywords: Opioids; Addiction; Business and Stakeholder Relations; Product Launch; Ethics; Society; Pharmaceutical Industry
Snowberg, Erik, Trevor Fetter, and Amy W. Schulman. "The Business of Pain: Johnson & Johnson and the Promise of Opioids (B)." Harvard Business School Supplement 720-423, December 2019.
- December 2019
- Case
Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem (Abridged)
By: Willy Shih
This case describes the efforts of the Bill & Melinda Gates Foundation to lower the cost of producing vaccines to prevent polio infections. It is an abridged version of HBS Case No. 620-021 with less emphasis on comparison between traditional and the new compact... View Details
Keywords: Vaccine; Manufacturing; Barriers To Entry; Production; Cost; Technological Innovation; Market Entry and Exit; Pharmaceutical Industry
Shih, Willy. "Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem (Abridged)." Harvard Business School Case 620-071, December 2019.
- November 2019
- Article
How Do Sales Efforts Pay Off? Dynamic Panel Data Analysis in the Nerlove-Arrow Framework
By: Doug J. Chung, Byungyeon Kim and Byoung G. Park
This paper evaluates the short- and long-term value of sales representatives’ detailing visits to different types of physicians. By understanding the dynamic effect of sales calls across heterogeneous physicians, we provide guidance on the design of optimal call... View Details
Keywords: Nerlove-Arrow Framework; Stock-of-goodwill; Dynamic Panel Data; Serial Correlation; Instrumental Variables; Sales Effectiveness; Detailing; Analytics and Data Science; Sales; Analysis; Performance Effectiveness; Pharmaceutical Industry
Chung, Doug J., Byungyeon Kim, and Byoung G. Park. "How Do Sales Efforts Pay Off? Dynamic Panel Data Analysis in the Nerlove-Arrow Framework." Management Science 65, no. 11 (November 2019): 5197–5218.
- August 2017 (Revised July 2018)
- Case
MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work
By: Elie Ofek and Amanda Dai
In June 2014, MannKind Corporation announced that after years of development and billions of dollars in expenses, the FDA had finally approved its drug, Afrezza. MannKind would thus be the only company with an inhalable insulin on the market. As an alternative to... View Details
Keywords: Health Care and Treatment; Product Launch; Product Positioning; Marketing Strategy; Adoption; Pharmaceutical Industry
Ofek, Elie, and Amanda Dai. "MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work." Harvard Business School Case 518-031, August 2017. (Revised July 2018.)
- January 2017
- Case
Medtronic: Making the Big Leap Forward (A)
By: William W. George and Monica Baraldi
In 2014, Medtronic was about to execute a $50 billion acquisition of Ireland-based Covidien. Medtronic CEO Omar Ishrak was committed to building the largest medical technology company in the world while broadening its ability to fulfill its mission of “alleviating... View Details
Keywords: Acquisition; Medtronic; Covidien; Mission; Tax Inversion; Business Strategy; Leadership; Mergers and Acquisitions; Pharmaceutical Industry; Republic of Ireland; Europe; Minnesota; United States
George, William W., and Monica Baraldi. "Medtronic: Making the Big Leap Forward (A)." Harvard Business School Case 317-031, January 2017.
- June 2016
- Teaching Plan
Terrapin Laboratory
By: Joseph B. Fuller and Andrew Otazo
This teaching plan accompanies the case "Terrapin Laboratory," HBS No. 315-098. That case describes the formation and rapid growth of a drug testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug... View Details
- March 2014 (Revised November 2020)
- Case
The Novartis Malaria Initiative
By: Michael Chu, Vincent Marie Dessain and Emilie Billaud
The Novartis Malaria Initiative was designed, as a result of a precedent–setting agreement with the World Health Organization in 2001, to provide a breakthrough treatment for malaria—"at no profit"—for public health systems. What had begun as an exemplary act of... View Details
Keywords: Health Care and Treatment; Product Marketing; Corporate Social Responsibility and Impact; Social Enterprise; Pharmaceutical Industry; Switzerland; Africa; Nigeria
Chu, Michael, Vincent Marie Dessain, and Emilie Billaud. "The Novartis Malaria Initiative." Harvard Business School Case 314-103, March 2014. (Revised November 2020.)
- November 1994
- Case
AB Astra: Growth with Quality
By: Mary E. Barth and David F. Hawkins
Barth, Mary E., and David F. Hawkins. "AB Astra: Growth with Quality." Harvard Business School Case 195-164, November 1994.
- April 2012 (Revised May 2012)
- Case
Merck: Operating Science-Based Business
By: Ananth Raman, Inga Maurer and William Schmidt
Merck is known for its commitment to investing in basic R&D. Are Merck's long-term investments justifiable when the firm faces extreme earnings pressure? View Details
Keywords: Science-Based Business; Management; Research and Development; Business and Shareholder Relations; Operations; Pharmaceutical Industry; United States
Raman, Ananth, Inga Maurer, and William Schmidt. "Merck: Operating Science-Based Business." Harvard Business School Case 612-082, April 2012. (Revised May 2012.)
- November 1991 (Revised August 2005)
- Case
Whelan Pharmaceuticals: Tax Factors and Global Site Selection
Whelan Pharmaceuticals, a U.S. company with $3 billion in sales, must decide where to manufacture its newest product. In considering possible sites, both foreign and U.S., the firm must identify and make trade-offs between tax, marketing, and manufacturing factors. View Details
Keywords: Globalized Firms and Management; Geographic Location; Cost vs Benefits; Production; Pharmaceutical Industry; United States
Wilson, G. Peter, and Jane Palley Katz. "Whelan Pharmaceuticals: Tax Factors and Global Site Selection." Harvard Business School Case 192-066, November 1991. (Revised August 2005.)
- October 2010 (Revised August 2016)
- Case
On Weldon's Watch: Recalls at Johnson & Johnson from 2009 to 2010
By: Clayton S. Rose, Sandra J. Sucher, Rachel Gordon and Matthew Preble
In October of 2010, Johnson & Johnson (J&J) was unable to extricate itself from a year long recall crisis that had subjected the firm to criticism from Congress and regulators, resulted in the resignation of one of the firm's most senior officers, and cost hundreds of... View Details
Keywords: Decision Choices and Conditions; Values and Beliefs; Leadership; Crisis Management; Corporate Social Responsibility and Impact; Organizational Change and Adaptation; Organizational Culture; Quality; Pharmaceutical Industry
Rose, Clayton S., Sandra J. Sucher, Rachel Gordon, and Matthew Preble. "On Weldon's Watch: Recalls at Johnson & Johnson from 2009 to 2010." Harvard Business School Case 311-029, October 2010. (Revised August 2016.)
- February 2010
- Supplement
Organization and Strategy at Millennium (B)
By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder CEO Mark... View Details
Keywords: Leading Change; Transformation; Decision Choices and Conditions; Crisis Management; Competitive Advantage; Commercialization; Selection and Staffing; Product Development; Organizational Change and Adaptation; Pharmaceutical Industry
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (B)." Harvard Business School Supplement 710-418, February 2010.
- June 2009 (Revised April 2017)
- Teaching Note
Merck: Managing Vioxx (A)-(G)
By: Robert Simons and Natalie Kindred
Teaching Note for [109080], [109081], [109082], [109083], [109084], [109085], and [109086]. View Details
- April 2009
- Supplement
Merck: Managing Vioxx (E)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Keywords: Leadership; Decision Choices and Conditions; Customer Focus and Relationships; Pharmaceutical Industry
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (E)." Harvard Business School Supplement 109-084, April 2009.
- 1999
- Chapter
The Economics of Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
Henderson, Rebecca M., and Iain Cockburn. "The Economics of Drug Discovery." Chap. 5 in Pharmaceutical Innovation, edited by Ralph Landau, Basil Achilladelis, and Alexander Scriabine, 308–331. Philadelphia: Chemical Heritage Press, 1999.
- August 2008 (Revised May 2009)
- Background Note
Note on Generic Drugs in the European Union
By: Robert C. Pozen and Elizabeth M. Leonard
Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S. View Details
Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Health Care and Treatment; Trademarks; Brands and Branding; Pharmaceutical Industry; European Union; United States
Pozen, Robert C., and Elizabeth M. Leonard. "Note on Generic Drugs in the European Union." Harvard Business School Background Note 309-019, August 2008. (Revised May 2009.)
- July 2008 (Revised September 2008)
- Case
Recent Developments in the Ranbaxy Case
By: Robert C. Pozen
This brief case describes settlements Indian drug maker Ranbaxy has made with Pfizer and AstraZeneca, as well as Daiichi Kangyo's purchase of a majority shareholding in Ranbaxy in 2008. View Details
Keywords: Mergers and Acquisitions; Patents; Lawsuits and Litigation; Ownership Stake; Pharmaceutical Industry; India
Pozen, Robert C. "Recent Developments in the Ranbaxy Case." Harvard Business School Case 609-010, July 2008. (Revised September 2008.)
- September 2006
- Teaching Note
Corporate Venture Capital at Eli Lilly (TN)
By: Richard G. Hamermesh and Erin Seefeld